Abstract. Analytical techniques capable of detecting changes in structure are necessary to monitor the quality of monoclonal antibody drug products. Ion mobility mass spectrometry offers an advanced mode of characterization of protein higher order structure. In this work, we evaluated the reproducibility of ion mobility mass spectrometry measurements and mobiligrams, as well as the suitability of this approach to differentiate between and/or characterize different monoclonal antibody drug products. Four mobiligram-derived metrics were identified to be reproducible across a multi-day window of analysis. These metrics were further applied to comparative studies of monoclonal antibody drug products representing different IgG subclasses, manufacturers, and lots. These comparisons resulted in some differences, based on the four metrics derived from ion mobility mass spectrometry mobiligrams. The use of collision-induced unfolding resulted in more observed differences. Use of summed charge state datasets and the analysis of metrics beyond drift time allowed for a more comprehensive comparative study between different monoclonal antibody drug products. Ion mobility mass spectrometry enabled detection of differences between monoclonal antibodies with the same target protein but different production techniques, as well as products with different targets. These differences were not always detectable by traditional collision cross section studies. Ion mobility mass spectrometry, and the added separation capability of collision-induced unfolding, was highly reproducible and remains a promising technique for advanced analytical characterization of protein therapeutics.
Introduction
O ver 40 monoclonal antibody (mAb) drug products have obtained FDA approval since the 1980s, when the first mAb was approved [1] . MAbs are used to treat a variety of conditions, including cancer, autoimmune disorders, inflammation, and infection. These mAb products are complex in nature as they are large (~150 kDa) molecules composed of multiple 25-30 kDa subunits. Subunits can be fused in a variety of combinations resulting in chimeric, human, humanized, and murine antibody types [2] . With the periods of patent exclusivity for several mAb products scheduled to end within the next few years, several follow-on biologics license applications (BLAs) are expected [3] . Several follow-on products have already been approved in Canadian and European markets [4] [5] [6] [7] [8] . The introduction of follow-on biologics has large financial implications as biologics account for 1% of total prescriptions, yet 28% of total prescription expenditures [9, 10] . Additionally, BLAs will continue to be submitted for new mAb drug products, including antibody-drug conjugates (ADCs) and mAb fragment products.
In order to ensure the safety and efficacy of these biologic drug products, analytical methods sensitive to the composition and structure of these biopharmaceutical products are necessary. Primary, secondary, tertiary, and quaternary structure, as well as other critical quality attributes (CQAs) may be affected by a wide array of factors, including changes in manufacturing processes and improper storage practices [11] [12] [13] . Several established techniques exist to characterize primary structure of protein therapeutics, such as peptide mapping using HPLC and top-down or bottom-up mass spectrometry (MS) [14] . A number of U.S. Pharmacopeia Convention (USP) monographs utilize HPLC for peptide mapping to confirm primary sequence. Primary structure determination can identify modifications such as glycosylation, oxidation, deamidation, and reduction of disulfide bonds. Although primary structure is useful in characterization of protein therapeutics, these modifications to primary structure may not reflect changes in higher levels of structure accurately, and thus other techniques are necessary for complete protein characterization [15] [16] [17] [18] .
Secondary, tertiary, and quaternary structures are often grouped under the term higher order structure (HOS). X-ray crystallography, nuclear magnetic resonance (NMR), circular dichroism (CD), and a number of spectroscopic techniques are routinely used for determination of secondary structure [19] [20] [21] . A recent study utilized deep ultraviolet resonance Raman (DUVRR) to sensitively characterize mAb secondary structure [22] . The study related changes in HOS to changes in drug efficacy.
Characterization of tertiary and quaternary HOS has proven to be analytically challenging. X-ray crystallography and NMR can be used; however, these techniques are limited by large sample amount requirements and molecular weight restrictions. Native MS has been employed for some protein therapeutic studies after significant advancements in instrumentation, namely high resolution mass spectrometers that allow for their accurate mass determination. These native MS studies often focus on glycoform identification and subunit stoichiometry [23] . Two MS-based methods have emerged for protein HOS characterization: hydrogen/deuterium exchange MS (HDX-MS) and ion mobility-MS (IM-MS) [24] . These MS-based methods are promising as they can be performed using relatively small amounts of sample, in contrast to traditional NMR and X-ray crystallographic approaches. HDX-MS enables detection of changes in conformation of a protein based on levels of deuterium incorporation. Regions of proteins that are distinct or exhibit conformational changes can be identified through differential experiments [25] . Because the technique incorporates a digestion step and coupling with HPLC, sequence information and post-translation modifications (PTMs) can be identified along with conformational changes. Significant advances have been made in HDX-MS, though challenges remain in obtaining reproducible results due to back-exchange, low temperatures, and decreased HPLC resolution. Automation advancements in the form of robotics exist; however, this system is expensive and requires a large footprint in lab space.
Native IM-MS allows ions to be separated by mass as well as conformation to potentially allow distinction between isobaric compounds if sufficient differences in their structures (and corresponding mobilities) are present. In IM-MS, ions travel through a drift tube and are separated based on their mobilities on a millisecond timescale. There are two main types of ion mobility mass spectrometers: drift tube (DTIMS) and traveling wave (TWIMS) [26, 27] . Both instruments enable the determination of a collision cross section (CCS), a characteristic of the ion that reflects its size and shape. In DTIMS, ions travel through a neutral drift gas, where smaller ions experience fewer collisions and travel faster down the drift tube than larger ions. DTIMS allows a direct calculation of CCS based on the measured drift time (t D ) [28] . TWIMS incorporates a traveling wave, which ions travel over for the length of the mobility region. Larger ions travel over the wave more frequently and thus take longer to reach the end of the flight tube. Smaller ions 'surf' the wave and reach the end of the flight tube faster [27] . Unlike DTIMS, t D measurements from TWIMS experiments are not commonly used to directly calculate CCS, though studies have shown it is possible [29] . Instead, a complex series of calculations are used to convert t D to CCS [30, 31] .
Larger proteins and drug products, such as mAbs, are difficult to resolve based on standard IM-MS experiments because of high molecular weights and complex structures [32] . Early experiments by Jarrold and Honea suggested that an annealing technique could aid in the separation of larger ions. In their study of silicon clusters, heating ions via a collision energy applied immediately prior to entrance into the drift tube resulted in better separation based on differences in structure caused by the annealing [33] . Zhong et al. have employed this concept in collision-induced unfolding (CIU) IM-MS experiments of proteins, applying some collision energy in the trap region (TCE) of a standard TWIMS QTOF instrument. Similar to the annealing experiments, different proteins may unfold in unique, specific patterns [32] .
Several studies of large proteins, protein complexes, and protein therapeutics have incorporated IM-MS or CIU IM-MS to determine CCS values [23, [30] [31] [32] [34] [35] [36] [37] [38] ; however, the suitability of this technique to compare and differentiate protein therapeutics has not yet been evaluated. In this work, we evaluated the suitability of IM-MS and CIU IM-MS measurements for analysis of protein therapeutic systems. Several metrics were reproducible across technical replicates. Method reproducibility was evaluated in a time-course experiment, in which several metrics were identified as reproducible in both IM-MS and CIU IM-MS experiments within a given timeframe. Multiple lots from individual drug products were also analyzed to identify any lot-to-lot variation. Further IM-MS and CIU IM-MS comparisons were made between different IgG subclasses, mAbs from the same subclass, mAbs with different targets, mAbs produced via different production techniques, and mAbs from different manufacturers.
Experimental
Materials MS-grade acetonitrile, MS-grade water, 7 kDa desalting columns, and 10 kDa molecular weight cutoff (MWCO) filters were purchased from Fisher Scientific (Pittsburgh, PA, USA). Alcohol dehydrogenase (ADH), ammonium acetate, bovine serum albumin (BSA), concanavalin A (ConA), and transthyretin (TTR) were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Adalimumab (Abbott, North Chicago, IL, USA), denosumab (Amgen, Thousand Oaks, CA, USA), infliximab (Johnson and Johnson, New Brunswick, NJ, USA), panitumumab (Amgen, Thousand Oaks, CA, USA), and rituximab (Genentech, South San Francisco, CA, USA) were purchased from the US marketplace. Rituximab (Dr. Reddy's Laboratories, Ltd., Hyderabad, India) was purchased from a non-U.S. marketplace. Sodium cesium iodide (NaCsI) was purchased from Waters (Manchester, UK). EconoTips emitters were purchased from New Objective (Woburn, MA, USA).
IM-MS Sample Preparation
MAbs were buffer exchanged into water using 10 kDa MWCO filters and concentrated to 100 μM. MAbs were further bufferexchanged and diluted to a working concentration of 2 μM in 150 mM ammonium acetate. Protein calibrant stocks for CCS were prepared at the following concentrations: 26 μM ADH, 15 μM BSA, 30 μM ConA, 13 μM PK, and 100 μM TTR in water. CCS calibrants were further buffer-exchanged and diluted to a working concentration of 5 μM in 150 mM ammonium acetate using 10 kDa MWCO filters.
IM-MS and CIU IM-MS Data Acquisition
Data were acquired on a Waters Synapt G2Si HDMS (Milford, MA, USA) equipped with an 8 kDa quadrupole. Settings were optimized as follows: source temperature 80 o C, capillary voltage 1.4 kV, sampling cone and source offset 100 V, trap bias 75 V, trap DC -6.5 V, trap entrance 0 V, trap exit -1 V, IM DC entrance 20, transfer DC exit 15, transfer collision energy 5 V, IMS wave height 40 V, transfer wave velocity 150 m/s, and transfer wave height 3 V. A wave ramp was used from 800 to 50 m/s for IMS wave velocity. Trap collision energy (TCE) was applied at 0, 50, 75, or 100 V. Cone gas was set to 40 L/h and no purge gas was used. Nano flow gas was set to 0.3 bars when needed. Data were acquired for 5 or 10 min.
IM-MS and CIU IM-MS Data Analysis
Chromatograms, extracted mobiligrams, and mass spectra were analyzed in MassLynx v4.1 (Waters). Mobility data were analyzed in DriftScope v2.5 (Waters). [31] . Cone gas was set to 40 L/h and no purge gas was used. Nano flow gas was set to 0.3 bar when needed. Data were acquired for 5 min at transfer wave heights of 8, 9, and 10 V.
Collision Cross Section Data Acquisition

Collision Cross Section Data Analysis
Calibrants used were alcohol dehydrogenase (ADH), bovine serum albumin (BSA), concanavalin A (ConA), and transthyretin (TTR). CCS was calculated using methods described by Ruotolo et al. and Bush et al. [30, 31] . Briefly, mobiligrams were extracted for the top 3 or 4 most abundant charge states for each calibrant at each transfer wave height. Plots of Ω' (CCS in nm 2 ) versus t D ' (ms) were fitted with a power regression model in Microsoft Excel. From mAb acquisitions, t D ' values were used to calculate Ω' and finally Ω.
Results and Discussion
Metric Selection and Evaluation of Metric Reproducibility Across Technical Replicates
Five metrics were initially evaluated across three technical replicates of the same rituximab (U.S.) sample for reproducibility and suitability as potential comparative values. The following mobiligram components were monitored to determine their suitability as a potential metric: drift time of the most intense peak (A) in the mobiligram (t d-A ), drift time of the second most intense peak (B) in the mobiligram (t d-B ), peak width at 50% maximum intensity (FWHM), peak width at 10% maximum intensity (FWTM), and the intensity ratio between t d-A and t d-B (peak intensity ratio, PIR). A mobiligram is shown in Figure 1 with each of the five metrics labeled.
PIR was observed to be inconsistent and dependent upon the width of the m/z selection window used in DriftScope (data not shown). Reproducible values between technical replicates of a single rituximab (U.S.) preparation were observed for the following four metrics: t d-A , t d-B , FWHM, and FWTM ( Table 1) . The values of these metrics were also reproducible across multiple (three) preparations of a rituximab (U.S.) sample (Supplementary Table S1 ).
As multiple charge states were observed for each mAb drug product analyzed, mobiligrams were constructed in a variety of ways in order to probe any changes between charge state and structure. Each of the top four charge states were independently extracted and mobiligrams analyzed; additionally, summed charge state mobiligrams were extracted and analyzed from the sums of the top two, three, or four most intense charge states. Metrics were reproducible in mobiligrams across all four charge states and the three summed charge state datasets. Average, standard deviation, and coefficient of variation (%RSD) values are shown in Table 1 for each of the top four most intense charge states individually as well as the summed top two, three, or four most intense charge states. Standard deviations of 0.00 reflected variation lower than reported precision. In IM-MS experiments (no applied TCE), the t d-A measurements (%RSD ≤ 1.44%, standard deviation ≤ 0.08 ms) were observed to be the most reproducible metrics, although the variability observed in the FWHM and FWTM measurements was also acceptable (FWHM: %RSD ≤ 7.02%, standard deviation ≤ 0.04 ms; FWTM: %RSD ≤ 9.02%, standard deviation ≤ 0.07 ms). In CIU IM-MS experiments (50, 75 or 100 V TCE), the Samples were also subjected to analysis using TCE values of 25, 125, 150, 175, and 200 V. CIU IM-MS experiments at 25 V TCE were the most variable (data not shown). Although 25 V TCE may be sufficient to induce some unfolding, this process may occur via a variety of pathways, translating to high variability in mobiligram profiles. If differences in CIU IM-MS energy profiles are not observed at 0, 50, 75, or 100 V TCE, a second round of experiments utilizing TCE settings of 125-200 V may be used as an additional potentially discriminatory measurement as these instrument settings also yielded reproducible results (data not shown).
While data extracted from individual charge states were highly reproducible, the order of the most intense charge states was not when TCE was applied. Figure 2 shows a series of CIU mobiligrams of the 24+ charge state of a rituximab (U.S.) sample at 0, 50, 75, and 100 V TCE with corresponding mass spectra of each acquisition. When TCE was applied, the charge state distributions (CSDs) were inconsistent. The top two and top four most intense charge states remained the same, suggesting the sums of these charge states were better suited for comparisons. This observation was consistent with above discussed results that indicated these two summed charge state datasets were the most reproducible across metrics in both IM-MS and CIU IM-MS experiments. 
Time-Course Metric Monitoring
The same dilutions of rituximab (2 μM in 150 mM ammonium acetate prepared on d 1) were also analyzed on days 2, 3, 4, and 5 post-preparation. By d 5, the CSD shifted to higher charge states (Supplementary Figure S1A) , suggesting a distinguishable change in structure, indicating samples must be analyzed before d 5 in order to obtain meaningful measurements. Metrics from mobiligrams extracted from d 5 samples were not evaluated for reproducibility because of the apparent structural change.
The 
Comparison of Multiple Lots of a Single Drug Product
Three lots of rituximab (U.S.) were prepared independently and analyzed by IM-MS and CIU IM-MS. Mobiligrams extracted from the sums of the top two or top four most intense charge states were analyzed and compared. Metrics t d-A and FWTM were consistent across all three lots at each TCE value (0, 50, 75, and 100 V), as shown in Figure 3a and c. FWHM was not consistent across all three lots when 50 or 75 V TCE were applied, as shown in Figure 3b . Intact mass analysis by highresolution MS did not indicate any differences between the three lots (data not shown). Although t d-A and FWTM were consistent across multiple lots of rituximab (U.S.), other comparison experiments in this study used averages of multiple lots when multiple lots were available to account for the differences observed in FWHM. In comparative studies where FWHM will not be utilized, multiple lots may not be necessary.
Comparison of Two mAb Subclasses: IgG1 and IgG2
Several IgG1 products and two IgG2 products were compared by using IM-MS and CIU IM-MS (Supplementary Table S4 (Figure 4a and b) . Drift times of IgG2 products were lower than those of IgG1 products. IgG2s contain more disulfide bonds and are more thermally stable. These data suggest IgG2 products were less unfolded at 75 and 100 V TCE, which may correspond to a more stable higher order structure or reflect the higher number of disulfide linkages for IgG2s relative to IgG1 molecules. When comparisons were made individually between specific IgG1 and IgG2 products, several significant differences were observed in metrics at some TCE voltages. Table 2 shows a panitumumab (IgG2) versus rituximab (U.S., IgG1) comparison. Red-filled cells indicate TCE conditions that resulted in significant differences between the specified metrics. These products were significantly different across all four metrics in both IM-MS and CIU IM-MS experiments. Other IgG1 and IgG2 comparisons are shown in Supplementary Table S7 . These data enabled direct comparisons between multiple IgG1 and IgG2 products by IM-MS and CIU IM-MS. Additionally, these data indicated the utility of CIU IM-MS experiments as an additional mode of separation when traditional IM-MS experiments were not able to distinguish between the two subclasses.
Comparison of Two IgG1mAbs with Different Targets: Rituximab (CD20) and Infliximab (TNF-α)
Within each IgG subclass, two additional factors were considered: target and production technique. Rituximab and infliximab are both produced as chimeric IgG1 mAbs; however, rituximab targets CD20 protein and infliximab targets tumor necrosis factor alpha (TNF-α). Three lots of rituximab (U.S.) and two lots of infliximab were averaged and metrics were analyzed from mobiligrams extracted from the sum of the top two most intense charge states. A difference in t d-A measurements was observed in IM-MS experiments, whereas a Table S6) difference in t d-B measurements was observed in CIU IM-MS experiments at 50 V TCE (Table 2 , red). Intact mass analysis indicated a mass difference of approximately 1000 Da between the two products (data not shown). Further differences were observed in FWHM and FWTM measurements at various TCE values. Figure 5a shows overlaid IM-MS mobiligrams from infliximab and rituximab (U.S.), with the inset highlighting the difference between t d-A . Although the difference in t d-A at 0 V TCE was significantly different, it was less obvious upon visual inspection. When 50 V of TCE were applied, the visual difference was more apparent, as shown in Figure 5b . Infliximab was observed as a single drift peak, whereas rituximab (U.S.) mobiligrams contained a second peak. These data further indicate the complementary utility of IM-MS and CIU IM-MS to distinguish between two mAbs from the same subclass.
Comparison of Two IgG1 mAbs with Same Target and Different Production Techniques: Infliximab (Chimeric) and Adalimumab (Human)
Both adalimumab and infliximab target TNF-α; however, adalimumab is a human mAb while infliximab is a chimeric mAb. One lot of adalimumab (due to lack of availability of additional lots) and two lots of infliximab were averaged, and Table 2 . The addition of CIU IM-MS experiments enabled distinction of these two similar mAb products, which were previously indistinguishable by IM-MS based on drift peak comparisons.
Comparison of an IgG1 Product (rituximab) from Different Manufacturers: U.S. and Non-U.S.
In analysis of follow-on BLAs, compared products will have the same target and production technique. Both U.S. and Non-U.S. rituximab products are chimeric mAbs that targeted CD20 protein. Only a difference in t d-A was observed in CIU IM-MS experiments at 50 V TCE. No differences in t d-B , FWHM, or FWTM were observed in either IM-MS or CIU IM-MS experiments. Supplementary Figure S3 shows overlaid IM-MS mobiligrams from U.S. and Non-U.S. rituximab products, with the inset highlighting the difference between t d-A measurements. Though t d-A measurements were significantly different statistically between the two species at a 50 V TCE, application of a Savitzky-Golay smoothing algorithm (window 3, order 2) resulted in the t d-A values overlapping perfectly. Even with additional smoothing (up to window 3, polynomial order 5), differences in the mobility profile between the two structures remain. Sufficient data is not available to determine if these differences are real or artifacts of the limited number of bins and bin sizes of IM-MS experiments on the Synapt platform that incorporate m/z values inclusive of intact monoclonal antibodies. The results shown here are not strong enough to be able to conclusively distinguish between the two rituximab drug products from two manufacturers. This may be attributable to a limitation of the platform (bin size and/or resolving power) or it may provide some evidence of the consistency of the product between manufacturers. What is most clear from this data is that while IM-MS may be used to clearly distinguish between mAb drug products with larger, more global differences, orthogonal methods are necessary to determine the similarity of difference between these two rituximab products. Although intact mass analysis did not indicate any differences between the two products (data not shown), a more detailed mass spectrometric approach (e.g., middle down or bottom up) may provide additional insights in the compositional differences, if any, between the two products. While there is no way to circumvent the bin size limitations on the Synapt G2si platform, future studies will attempt to explore alternative IM-MS platforms that may provide smaller bin sizes and yield more data points per peak in the mobiligram.
Collision Cross Sections
Typical protein comparisons by IM-MS use t d-A measurements to calculate a collision cross section (CCS, Ω). In TWIMS, these calculations are based on calibration curves constructed from protein standards of known CCS. Protein standards are selected to bracket the molecular weight of the sample of interest; however, options are limited to those available in online databases [30, [40] [41] [42] . Additionally, calibration curves are obtained under mild source conditions and no collision energy to preserve native state conformations. These mild conditions indicate that CCS calculations from CIU IM-MS experiments extrapolated as CIU are not employed during Previously discussed comparisons were repeated under CCS-compatible source conditions. The top three most intense charge states were compared. No grouping of IgG1 or IgG2 products was observed based on CCS (Supplementary Figure S2A-C) . No significant differences in CCS were observed in adalimumab-infliximab comparisons or U.S.-Non-U.S. rituximab comparisons. When infliximab and rituximab were compared, CCS measurements of all three charge states were significantly different. When panitumumab and rituximab were compared, CCS measurements of the 23+ charge states were significantly different; however, CCS measurements of the remaining two charge states were not significantly different. Previously discussed IM-MS and CIU IM-MS experiments resulted in t d-A differences of 1% to 4%, which corresponded to differences in CCS of 0.5 to 1.8 nm 2 . Standard deviations of CCS measurements ranged from 0.00 to 0.61 nm 2 , thus 2% to 4% t d-A differences were well outside this range whereas 1% differences were not. Direct comparison of mAbs utilizing the four metrics appeared to be more sensitive in distinguishing between previously discussed products.
Conclusions
As the number of protein therapeutics entering the market continues to grow, highly sensitive analytical techniques will be imperative to ensure product quality. IM-MS was found to be an adequate technique for the characterization of a specific class of protein therapeutics, monoclonal antibodies. The IM-MS measurements displayed low variability when technical replicates or multiple preparations of a mAb drug product were analyzed. Reproducibility was evaluated based on four metrics selected to describe the mobiligram of a mAb product: t d-A , t d-B , FWHM, and FWTM. An additional mode of separation could be obtained when necessary by employing CIU IM-MS experiments, which was found to provide similar reproducibility of all four metrics across technical replicates and multiple preparations of a mAb drug product. This reproducibility continued across a 4-d window after initial sample preparation, widening experimental timeframes within which meaningful comparisons can be made.
Although individual charge states are traditionally used in IM-MS studies, mobiligrams comprised of the sums of the two or four most intense charge states were also analyzed as a way to obtain a more global measurement profile of the mAb drug product. These summed charge state datasets exhibited higher reproducibility and incorporated multiple charge states for a more comprehensive analysis. The utilization of summed charge state datasets may enable a standardized analysis versus choosing one or more individual charge states to make comparisons. Multiple lots of one product were reproducible across all metrics when the sum of the top two charge states was used. Specific comparisons between IgG1 and IgG2 products resulted in significant differences across all metrics. The consistency of these results was not observed across all individual charge states, further indicating the utility of summed charge state datasets. As a mAb is present in multiple charge states and structures simultaneously, the use of multiple charge states to generate mobiligrams will enable comparisons to more accurately reflect the entire protein population instead of only the structure for a single charge state.
Comparison of IgG1 products with the same target but different production techniques highlighted the use of CIU IM-MS, as TCE resulted in significantly different mobiligram profiles for adalimumab and infliximab. Comparative studies between IgG1 products with different targets yielded differences in all metrics, whereas a difference in t d-A was observed in comparative studies between two rituximab products from different manufacturers. This difference in t d-A observed between the two products (U.S. and Non-U.S.) was statistically significant, but small (1%). Upon smoothing of the data, the t d-A became identical, although the mobility profiles continued to display some slight differences, even with additional smoothing. Although it has been demonstrated that IM-MS can be used to make comparisons between many different systems, this result highlights the need for orthogonal methods to also be used when making comparisons between mAb drug products. Additionally, the differences obtained without smoothing may be indicative of the limited digital resolution of the platform instead of real chemical differences. Future studies may employ the use of stressors to further distinguish between products from different manufacturers. Additionally, future studies will endeavor to use alternative IM-MS platforms that may offer increased digital resolution and, thus, more points per peak in the mobiligram. In this work, we demonstrated the suitability of IM-MS and CIU IM-MS to compare protein therapeutics, specifically mAb drug products. This reproducible technique may be used to further characterize structural changes in a variety of protein therapeutics, including newer molecules such as antibody-drug conjugates and fusion proteins. We suggest this proposed framework for characterization and comparative profiling of mAbs using IM-MS and CIU IM-MS.
